{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:46:01Z","timestamp":1782715561968,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Natural Science Foundation of Shanghai","award":["22ZR1457100 and 24ZR1463600"],"award-info":[{"award-number":["22ZR1457100 and 24ZR1463600"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11064-026-04802-x","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:15:15Z","timestamp":1780470915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Myelin-Derived Peptide NSDP1 Suppresses Neuroinflammation and Attenuates Demyelination in Chronic Cuprizone-Fed Mice via Modulation of cGAS\u2013STING Signaling"],"prefix":"10.1007","volume":"51","author":[{"given":"Junjie","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingze","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingcong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"4802_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103449","volume":"22","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wang J, Feng J (2023) Multiple Sclerosis and pregnancy: pathogenesis, influencing factors, and treatment options. Autoimmun Rev 22:103449","journal-title":"Autoimmun Rev"},{"key":"4802_CR2","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1001\/jamaneurol.2024.2876","volume":"81","author":"J Graf","year":"2024","unstructured":"Graf J, Akmatov MK, Meuth SG, Tremlett H, Holstiege J (2024) Updated Multiple Sclerosis Incidence, 2015\u20132022. JAMA Neurol 81:1100\u20131102","journal-title":"JAMA Neurol"},{"key":"4802_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41582-021-00556-y","volume":"17","author":"N Koch-Henriksen","year":"2021","unstructured":"Koch-Henriksen N, Magyari M (2021) Apparent changes in the epidemiology and severity of multiple sclerosis. Nat Rev Neurol 17:676\u2013688","journal-title":"Nat Rev Neurol"},{"key":"4802_CR4","first-page":"225","volume":"26","author":"MA Sotgiu","year":"2022","unstructured":"Sotgiu MA, Piga G, Mazzarello V, Zarbo IR, Carta A, Saderi L, Sotgiu S, Conti M, Saba L, Crivelli P (2022) Corpus callosum volumetrics and clinical progression in early multiple sclerosis. Eur Rev Med Pharmacol Sci 26:225\u2013231","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"4802_CR5","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1001\/jama.2022.14236","volume":"328","author":"R Marcus","year":"2022","unstructured":"Marcus R (2022) What Is Multiple Sclerosis? JAMA 328:2078","journal-title":"JAMA"},{"key":"4802_CR6","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC (2020) Treatment of Multiple Sclerosis: A Review. Am J Med 133:1380\u20131390e1382","journal-title":"Am J Med"},{"key":"4802_CR7","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2023.03.008","volume":"186","author":"M Charabati","year":"2023","unstructured":"Charabati M, Wheeler MA, Weiner HL, Quintana FJ (2023) Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting. Cell 186:1309\u20131327","journal-title":"Cell"},{"key":"4802_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/science.adx0043","volume":"388","author":"FD Shi","year":"2025","unstructured":"Shi FD, Yong VW (2025) Neuroinflammation across neurological diseases. Science 388:eadx0043","journal-title":"Science"},{"key":"4802_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","volume":"47","author":"C Lucchinetti","year":"2000","unstructured":"Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707\u2013717","journal-title":"Ann Neurol"},{"key":"4802_CR10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/ana.1255","volume":"50","author":"JW Prineas","year":"2001","unstructured":"Prineas JW, Kwon EE, Cho ES, Sharer LR, Barnett MH, Oleszak EL, Hoffman B, Morgan BP (2001) Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 50:646\u2013657","journal-title":"Ann Neurol"},{"key":"4802_CR11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12974-024-03267-5","volume":"21","author":"J Langlois","year":"2024","unstructured":"Langlois J, Lange S, Ebeling M, Macnair W, Schmucki R, Li C, DeGeer J, Sudharshan TJJ, Yong VW, Shen YA, Harp C, Collin L, Keaney J (2024) Fenebrutinib, a Bruton\u2019s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways. J Neuroinflammation 21:276","journal-title":"J Neuroinflammation"},{"key":"4802_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1572140","volume":"16","author":"WG Zhang","year":"2025","unstructured":"Zhang WG, Zheng XR, Yao Y, Sun WJ, Shao BZ (2025) The role of NLRP3 inflammasome in multiple sclerosis: pathogenesis and pharmacological application. Front Immunol 16:1572140","journal-title":"Front Immunol"},{"key":"4802_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114902","volume":"159","author":"R Dhapola","year":"2025","unstructured":"Dhapola R, Paidlewar M, Kumari S, Sharma P, Vellingiri B, Medhi B, HariKrishnaReddy D (2025) cGAS-STING and neurodegenerative diseases: A molecular crosstalk and therapeutic perspective. Int Immunopharmacol 159:114902","journal-title":"Int Immunopharmacol"},{"key":"4802_CR14","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","volume":"21","author":"A Decout","year":"2021","unstructured":"Decout A, Katz JD, Venkatraman S, Ablasser A (2021) The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol 21:548\u2013569","journal-title":"Nat Rev Immunol"},{"key":"4802_CR15","doi-asserted-by":"crossref","unstructured":"Verma SC, Enee E, Manasse K, Rebhi F, Penc A, Romeo-Guitart D, Bui Thi C, Titeux M, Oury F, Fillatreau S, Liblau R, Diana J (2024) Cathelicidin antimicrobial peptide expression in neutrophils and neurons antagonistically modulates neuroinflammation. J Clin Invest 135","DOI":"10.1172\/JCI184502"},{"key":"4802_CR16","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1007\/s00216-011-5589-8","volume":"402","author":"S Pavan","year":"2012","unstructured":"Pavan S, Berti F (2012) Short peptides as biosensor transducers. Anal Bioanal Chem 402:3055\u20133070","journal-title":"Anal Bioanal Chem"},{"key":"4802_CR17","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1021\/acs.jmedchem.7b00318","volume":"61","author":"A Henninot","year":"2018","unstructured":"Henninot A, Collins JC, Nuss JM (2018) The Current State of Peptide Drug Discovery: Back to the Future? J Med Chem 61:1382\u20131414","journal-title":"J Med Chem"},{"key":"4802_CR18","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1021\/acs.jproteome.1c00295","volume":"20","author":"RE Foreman","year":"2021","unstructured":"Foreman RE, George AL, Reimann F, Gribble FM, Kay RG (2021) Peptidomics: A Review of Clinical Applications and Methodologies. J Proteome Res 20:3782\u20133797","journal-title":"J Proteome Res"},{"key":"4802_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26020430","author":"V Apostolopoulos","year":"2021","unstructured":"Apostolopoulos V, Bojarska J, Chai TT, Elnagdy S, Kaczmarek K, Matsoukas J, New R, Parang K, Lopez OP, Parhiz H, Perera CO, Pickholz M, Remko M, Saviano M, Skwarczynski M, Tang Y, Wolf WM, Yoshiya T, Zabrocki J, Zielenkiewicz P, AlKhazindar M, Barriga V, Kelaidonis K, Sarasia EM, Toth I (2021) A global review on short peptides: frontiers and perspectives. Molecules. https:\/\/doi.org\/10.3390\/molecules26020430","journal-title":"Molecules"},{"key":"4802_CR20","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.15846","volume":"11","author":"X Dong","year":"2023","unstructured":"Dong X, Sun S, Li J, Shen S, Chen W, Li T, Li X (2023) Identification of potential functional peptides involved in demyelinating injury in the central nervous system. PeerJ 11:e15846","journal-title":"PeerJ"},{"key":"4802_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25168877","author":"J Ni","year":"2024","unstructured":"Ni J, Zhao J, Chen H, Liu W, Le M, Guo X, Dong X (2024) 2,3-Diphosphoglyceric acid alleviating hypoxic-ischemic brain damage through p38 MAPK modulation. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25168877","journal-title":"Int J Mol Sci"},{"key":"4802_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","volume":"20","author":"M Muttenthaler","year":"2021","unstructured":"Muttenthaler M, King GF, Adams DJ, Alewood PF (2021) Trends in peptide drug discovery. Nat Rev Drug Discov 20:309\u2013325","journal-title":"Nat Rev Drug Discov"},{"key":"4802_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","volume":"20","author":"K Fosgerau","year":"2015","unstructured":"Fosgerau K, Hoffmann T (2015) Peptide therapeutics: current status and future directions. Drug Discov Today 20:122\u2013128","journal-title":"Drug Discov Today"},{"key":"4802_CR24","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","volume":"26","author":"JL Lau","year":"2018","unstructured":"Lau JL, Dunn MK (2018) Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem 26:2700\u20132707","journal-title":"Bioorg Med Chem"},{"key":"4802_CR25","doi-asserted-by":"publisher","first-page":"440","DOI":"10.4049\/jimmunol.140.2.440","volume":"140","author":"PJ Higgins","year":"1988","unstructured":"Higgins PJ, Weiner HL (1988) Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol 140:440\u2013445","journal-title":"J Immunol"},{"key":"4802_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.clim.2012.05.010","volume":"144","author":"AH Badawi","year":"2012","unstructured":"Badawi AH, Siahaan TJ (2012) Immune modulating peptides for the treatment and suppression of multiple sclerosis. Clin Immunol 144:127\u2013138","journal-title":"Clin Immunol"},{"key":"4802_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00726-021-03111-7","volume":"54","author":"V Martinsen","year":"2022","unstructured":"Martinsen V, Kursula P (2022) Multiple sclerosis and myelin basic protein: insights into protein disorder and disease. Amino Acids 54:99\u2013109","journal-title":"Amino Acids"},{"key":"4802_CR28","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/80516","volume":"6","author":"B Bielekova","year":"2000","unstructured":"Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R (2000) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83\u201399) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6:1167\u20131175","journal-title":"Nat Med"},{"key":"4802_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1017\/S0317167100045078","volume":"10","author":"MK Dasgupta","year":"1983","unstructured":"Dasgupta MK, Catz I, Warren KG, McPherson TA, Dossetor JB, Carnegie PR (1983) Myelin basic protein: a component of circulating immune complexes in multiple sclerosis. Can J Neurol Sci 10:239\u2013243","journal-title":"Can J Neurol Sci"},{"key":"4802_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0022-510X(93)90221-J","volume":"115","author":"KG Warren","year":"1993","unstructured":"Warren KG, Catz I (1993) Autoantibodies to myelin basic protein within multiple sclerosis central nervous system tissue. J Neurol Sci 115:169\u2013176","journal-title":"J Neurol Sci"},{"key":"4802_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0022-510X(95)00187-7","volume":"133","author":"KG Warren","year":"1995","unstructured":"Warren KG, Catz I (1995) Administration of myelin basic protein synthetic peptides to multiple sclerosis patients. J Neurol Sci 133:85\u201394","journal-title":"J Neurol Sci"},{"key":"4802_CR32","doi-asserted-by":"publisher","first-page":"504","DOI":"10.4049\/jimmunol.161.1.504","volume":"161","author":"EA Leadbetter","year":"1998","unstructured":"Leadbetter EA, Bourque CR, Devaux B, Olson CD, Sunshine GH, Hirani S, Wallner BP, Smilek DE, Happ MP (1998) Experimental autoimmune encephalomyelitis induced with a combination of myelin basic protein and myelin oligodendrocyte glycoprotein is ameliorated by administration of a single myelin basic protein peptide. J Immunol 161:504\u2013512","journal-title":"J Immunol"},{"key":"4802_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jneuroim.2015.07.004","volume":"286","author":"CJ Perera","year":"2015","unstructured":"Perera CJ, Lees JG, Duffy SS, Makker PG, Fivelman B, Apostolopoulos V, Moalem-Taylor G (2015) Effects of active immunisation with myelin basic protein and myelin-derived altered peptide ligand on pain hypersensitivity and neuroinflammation. J Neuroimmunol 286:59\u201370","journal-title":"J Neuroimmunol"},{"key":"4802_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cellimm.2012.11.004","volume":"280","author":"EW Loo","year":"2012","unstructured":"Loo EW, Krantz MJ, Agrawal B (2012) High dose antigen treatment with a peptide epitope of myelin basic protein modulates T cells in multiple sclerosis patients. Cell Immunol 280:10\u201315","journal-title":"Cell Immunol"},{"key":"4802_CR35","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1053\/sarh.2001.27736","volume":"31","author":"A VanderBorght","year":"2001","unstructured":"VanderBorght A, Geusens P, Raus J, Stinissen P (2001) The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. Semin Arthritis Rheum 31:160\u2013175","journal-title":"Semin Arthritis Rheum"},{"key":"4802_CR36","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/eji.1830220431","volume":"22","author":"T Olsson","year":"1992","unstructured":"Olsson T, Sun J, Hillert J, Hojeberg B, Ekre HP, Andersson G, Olerup O, Link H (1992) Increased numbers of T cells recognizing multiple myelin basic protein epitopes in multiple sclerosis. Eur J Immunol 22:1083\u20131087","journal-title":"Eur J Immunol"},{"key":"4802_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1089\/nat.2023.0018","volume":"34","author":"T Metz","year":"2024","unstructured":"Metz T, Welling MM, Suidgeest E, Nieuwenhuize E, de Vlaam T, Curtis D, Hailu TT, van der Weerd L, van Roon-Mom WMC (2024) Biodistribution of radioactively labeled splice modulating antisense oligonucleotides after intracerebroventricular and intrathecal injection in mice. Nucleic Acid Ther 34:26\u201334","journal-title":"Nucleic Acid Ther"},{"key":"4802_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111709","volume":"140","author":"A Asgari Taei","year":"2021","unstructured":"Asgari Taei A, Nasoohi S, Hassanzadeh G, Kadivar M, Dargahi L, Farahmandfar M (2021) Enhancement of angiogenesis and neurogenesis by intracerebroventricular injection of secretome from human embryonic stem cell-derived mesenchymal stem cells in ischemic stroke model. Biomed Pharmacother 140:111709","journal-title":"Biomed Pharmacother"},{"key":"4802_CR39","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1600-0463.2012.02882.x","volume":"120","author":"S Wergeland","year":"2012","unstructured":"Wergeland S, Torkildsen O, Myhr KM, Mork SJ, Bo L (2012) The cuprizone model: regional heterogeneity of pathology. APMIS 120:648\u2013657","journal-title":"APMIS"},{"key":"4802_CR40","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/glia.23937","volume":"69","author":"H Kaddatz","year":"2021","unstructured":"Kaddatz H, Joost S, Nedelcu J, Chrzanowski U, Schmitz C, Gingele S, Gudi V, Stangel M, Zhan J, Santrau E, Greiner T, Frenz J, Muller-Hilke B, Muller M, Amor S, van der Valk P, Kipp M (2021) Cuprizone-induced demyelination triggers a CD8-pronounced T cell recruitment. Glia 69:925\u2013942","journal-title":"Glia"},{"key":"4802_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.511","volume":"5","author":"Q Li","year":"2024","unstructured":"Li Q, Wu P, Du Q, Hanif U, Hu H, Li K (2024) cGAS-STING, an important signaling pathway in diseases and their therapy. MedComm (2020) 5:e511","journal-title":"MedComm (2020)"},{"key":"4802_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107063","volume":"201","author":"X He","year":"2024","unstructured":"He X, Wedn A, Wang J, Gu Y, Liu H, Zhang J, Lin Z, Zhou R, Pang X, Cui Y (2024) IUPHAR ECR review: the cGAS-STING pathway: novel functions beyond innate immune and emerging therapeutic opportunities. Pharmacol Res 201:107063","journal-title":"Pharmacol Res"},{"key":"4802_CR43","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.immuni.2024.03.010","volume":"57","author":"S Castro-Gomez","year":"2024","unstructured":"Castro-Gomez S, Heneka MT (2024) Innate immune activation in neurodegenerative diseases. Immunity 57:790\u2013814","journal-title":"Immunity"},{"key":"4802_CR44","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1111\/cns.14157","volume":"29","author":"C Ma","year":"2023","unstructured":"Ma C, Liu Y, Li S, Ma C, Huang J, Wen S, Yang S, Wang B (2023) Microglial cGAS drives neuroinflammation in the MPTP mouse models of Parkinson\u2019s disease. CNS Neurosci Ther 29:2018\u20132035","journal-title":"CNS Neurosci Ther"},{"key":"4802_CR45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.brainresbull.2021.03.010","volume":"171","author":"GL Jiang","year":"2021","unstructured":"Jiang GL, Yang XL, Zhou HJ, Long J, Liu B, Zhang LM, Lu D (2021) cGAS knockdown promotes microglial M2 polarization to alleviate neuroinflammation by inhibiting cGAS-STING signaling pathway in cerebral ischemic stroke. Brain Res Bull 171:183\u2013195","journal-title":"Brain Res Bull"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-026-04802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-026-04802-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-026-04802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:04:11Z","timestamp":1782713051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-026-04802-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4802"],"URL":"https:\/\/doi.org\/10.1007\/s11064-026-04802-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8298082\/v1","asserted-by":"object"}]},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The experimental protocols received ethical approval from the Institutional Animal Care Committee at Tongren Hospital of Chinese Medicine (Approval ID: 2022-045-01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"185"}}